Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus FYCOMPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus FYCOMPA.
CENOBAMATE vs FYCOMPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Category C
Category C
Anticonvulsant
Anticonvulsant